CRISPR Therapeutics AG (CRSP) Cash from Operations (2015 - 2026)
CRISPR Therapeutics AG (CRSP) posted Cash from Operations of 108897000.0 for Q1 2026, down 17.66% sequentially from 92553000.0 in Q4 2025, and down 101.86% YoY from 5857095173.48 in Q1 2025.
CRISPR Therapeutics AG (CRSP) Cash from Operations (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Cash from Operations for 12 years, with the latest figure at 108897000.0 in Q1 2026.
- Quarterly Cash from Operations fell 101.86% year-over-year to 108897000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 399964000.0 (down 30.51% YoY) and the FY2025 annual result came in at 345014000.0, down 141.65% from the prior year.
- Cash from Operations fell to 108897000.0 in Q1 2026 per CRSP's latest filing, from 92553000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 109752000.0 in Q1 2024 and troughed at 141956000.0 in Q2 2022.
- A 5-year average of 79576529.41 and a median of 96073000.0 in 2023 frame the typical range for Cash from Operations.
- The widest YoY moves for Cash from Operations: up 1147.32% in 2024, down 168.25% in 2024.
- Over 5 years, Cash from Operations stood at 113328000.0 in 2022, then grew by 15.23% to 96073000.0 in 2023, then soared by 47.92% to 50031000.0 in 2024, then sank by 84.99% to 92553000.0 in 2025, then decreased by 17.66% to 108897000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 108897000.0, 92553000.0, and 84634000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | -83.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -83.50 Mn |
| Jun 30, 2026 | -83.50 Mn |
| Mar 31, 2026 | -108.90 Mn |
| Mar 31, 2026 | -108.90 Mn |
| Dec 31, 2025 | -92.55 Mn |
| Dec 31, 2025 | -92.55 Mn |
| Sep 30, 2025 | -84.63 Mn |
| Sep 30, 2025 | -84.63 Mn |
| Jun 30, 2025 | -113.88 Mn |
| Jun 30, 2025 | -113.88 Mn |
| Mar 31, 2025 | -53.95 Mn |
| Mar 31, 2025 | -53.95 Mn |
| Dec 31, 2024 | -50.03 Mn |
| Dec 31, 2024 | -50.03 Mn |
| Sep 30, 2024 | -106.91 Mn |
| Sep 30, 2024 | -106.91 Mn |
| Jun 30, 2024 | -95.58 Mn |
| Jun 30, 2024 | -95.58 Mn |
| Mar 31, 2024 | 109.75 Mn |
| Mar 31, 2024 | 109.75 Mn |